Impact Investment Bay Area Lyme Foundation has launched an impact investment fund and engages in venture-style oversight of a portfolio of Lyme-focused diagnostics and therapeutics. This signals openness to strategic partnerships, co-investment opportunities, and vendor relationships that align with mission-driven outcomes.

Diagnostic Ecosystem Recent investments in Galaxy Diagnostics and LymeLess Health indicate a strong focus on advancing testing technologies. This creates sales opportunities for bioinformatics, data analytics, cloud-enabled lab workflows, and regulatory-ready diagnostic platforms that can integrate with partner ecosystems.

Executive Leadership New executive leadership, including an Executive Director appointed in 2025, suggests evolving strategic priorities and procurement approaches. Use a consultative, outcome-focused outreach to align solutions with the foundation’s expanded governance and program oversight.

Strategic Partnerships Longstanding collaborations with public entities (e.g., City of San Jose Environmental Services) and a growing network of scientific collaborators indicate a receptive posture toward training, awareness campaigns, and field deployment programs that can be monetized through technology, services, and educational content.

Funding Scale Annual revenue in the mid-range of non-profit funding and a donor-supported model that covers admin costs but directs funds to programs point to scalable partnership opportunities in grant-backed solutions, sponsored research, and ROI-driven programs for diagnostics, prevention, and patient outcomes.